26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...
5 December 2023 - Public comment period now open until 9 January 2024; requests to make oral comment during public ...
28 November 2023 - Public comment period now open until 22 December 2023; requests to make oral comment during public meeting ...
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced ...
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per ...
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit ...
16 February 2023 - The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of resmetirom ...
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...